IN2013MN01218A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MN01218A IN2013MN01218A IN1218MUN2013A IN2013MN01218A IN 2013MN01218 A IN2013MN01218 A IN 2013MN01218A IN 1218MUN2013 A IN1218MUN2013 A IN 1218MUN2013A IN 2013MN01218 A IN2013MN01218 A IN 2013MN01218A
- Authority
- IN
- India
- Prior art keywords
- charge
- drugs
- designing
- biopolymers
- synthesizing
- Prior art date
Links
- 229920001222 biopolymer Polymers 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 4
- 230000003449 preventive effect Effects 0.000 abstract 3
- 230000002194 synthesizing effect Effects 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 101710163270 Nuclease Proteins 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002547 new drug Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- 230000029936 alkylation Effects 0.000 abstract 1
- 238000005804 alkylation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- -1 halogen carboxylic acids Chemical class 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Food Science & Technology (AREA)
- Computing Systems (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2010/000694 WO2012070968A1 (ru) | 2010-11-22 | 2010-11-22 | Способ молекулярного дизайна и синтеза лечебных и профилактических лекарст- венных препаратов |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013MN01218A true IN2013MN01218A (de) | 2015-06-12 |
Family
ID=46065142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1218MUN2013 IN2013MN01218A (de) | 2010-11-22 | 2010-11-22 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120130699A1 (de) |
| EP (1) | EP2644617A4 (de) |
| EA (1) | EA025399B1 (de) |
| IN (1) | IN2013MN01218A (de) |
| WO (1) | WO2012070968A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2527142A1 (de) | 2011-05-24 | 2012-11-28 | Cryovac, Inc. | Mehrschichtige Polyesterfolie für Fertiggerichte |
| US20140220556A1 (en) * | 2013-02-06 | 2014-08-07 | Artur Martynov | Method of Design and Synthesis of a New Drug |
| RU2646885C1 (ru) * | 2017-02-15 | 2018-03-12 | Владимир Николаевич Коваль | Олигопептидная композиция |
| US11191806B2 (en) * | 2018-05-04 | 2021-12-07 | Boris Farber | Polymyxin-based pharmaceutical composition for treating infectious diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5495423A (en) | 1993-10-25 | 1996-02-27 | Trustees Of Boston University | General strategy for vaccine and drug design |
| AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
| US5854992A (en) | 1996-09-26 | 1998-12-29 | President And Fellows Of Harvard College | System and method for structure-based drug design that includes accurate prediction of binding free energy |
| ATE359561T1 (de) | 1997-06-02 | 2007-05-15 | Univ Johns Hopkins | Rechnerverfahren freie energieberechnung für ligandenentwurf verwendend und die voraussage von bindenden zielen |
| US7396919B1 (en) * | 1998-07-17 | 2008-07-08 | Mirus Bio Corporation | Charge reversal of polyion complexes |
| US20030088366A1 (en) * | 2001-07-13 | 2003-05-08 | Neurocrine Biosciences, Inc. | Computational method for the design of screening libraries for superfamilies of molecular targets having therapeutic utility |
| US20040167090A1 (en) * | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| US7365058B2 (en) * | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
-
2010
- 2010-11-22 IN IN1218MUN2013 patent/IN2013MN01218A/en unknown
- 2010-11-22 EP EP10859902.8A patent/EP2644617A4/de not_active Withdrawn
- 2010-11-22 EA EA201300490A patent/EA025399B1/ru not_active IP Right Cessation
- 2010-11-22 WO PCT/RU2010/000694 patent/WO2012070968A1/ru not_active Ceased
-
2011
- 2011-02-01 US US12/931,469 patent/US20120130699A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120130699A1 (en) | 2012-05-24 |
| WO2012070968A1 (ru) | 2012-05-31 |
| EP2644617A1 (de) | 2013-10-02 |
| EA201300490A1 (ru) | 2014-03-31 |
| EP2644617A4 (de) | 2014-05-14 |
| EA025399B1 (ru) | 2016-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002094A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153) | |
| MX2024000208A (es) | Restos de administracion terapeutica novedosos y usos de estos. | |
| MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
| Braný et al. | Effect of cold atmospheric plasma on epigenetic changes, DNA damage, and possibilities for its use in synergistic cancer therapy | |
| JOP20210207B1 (ar) | مركبات ترابطية مستهدفة | |
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| MX2011008430A (es) | Metodos y composiciones para diagnostico y tratamiento del cancer. | |
| BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
| EP4273782A3 (de) | System, vorrichtung und verfahren zur bereitstellung einer therapie oder einer heilung für krebs und andere pathologische zustände | |
| EP3747457A3 (de) | Faktor-1-protein, faktor-2-protein und inhibitoren davon zur verwendung bei der behandlung und prävention von erkrankungen | |
| CO2022003552A2 (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| MX2014009909A (es) | Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado. | |
| IN2013MN01218A (de) | ||
| CY1119233T1 (el) | Προϊοντα γονιδιων εκφραζομενα διαφορικα μεσα σε ογκους και εφαρμογη αυτων | |
| MX2017001898A (es) | Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales. | |
| BR112012020373A8 (pt) | anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico | |
| NO20054769D0 (no) | Substituerte fenylalkansyrer | |
| EA201491726A1 (ru) | Конъюгаты бороновых кислот олигонуклеотидных аналогов | |
| MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
| BR112018006687A2 (pt) | prevenção, tratamento e reversão de doenças utilizando montantes terapeuticamente eficazes de ácidos graxos ativos | |
| DE602006020501D1 (de) | Synthetische mecp2-sequenz für die proteinersatztherapie | |
| RU2015128766A (ru) | Нереплицируемые происходящие от вирусов частицы и их применение | |
| PH12019502442A1 (en) | Variants of human bmp7 protein | |
| UY32830A (es) | Procedimientos para la sintesis estereoselectiva de heterocíclos bicíclicos | |
| EA201300489A1 (ru) | Модифицированные антикомплементарные олигонуклеотиды с противораковыми свойствами и способ их получения |